Shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) saw strong trading volume on Monday . 171,364 shares traded hands during mid-day trading, an increase of 46% from the previous session’s volume of 117,509 shares.The stock last traded at $2.11 and had previously closed at $2.17.

A number of equities analysts have weighed in on the stock. Zacks Investment Research raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Monday. Maxim Group reaffirmed a “buy” rating and issued a $5.00 target price on shares of Cytori Therapeutics in a research note on Wednesday, July 20th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of Cytori Therapeutics in a research note on Tuesday, June 28th.

The company has a 50 day moving average of $2.05 and a 200 day moving average of $2.83. The firm’s market capitalization is $28.93 million.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by $0.38. During the same quarter in the previous year, the business earned ($0.07) EPS. The company had revenue of $2.90 million for the quarter, compared to analyst estimates of $2.05 million. The business’s quarterly revenue was up 26.1% compared to the same quarter last year. On average, equities analysts expect that Cytori Therapeutics Inc. will post ($1.59) earnings per share for the current year.

Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.